For most research contexts, 9 mg therefore represents a more favourable efficacy-to-tolerability balance than 12 mg
Who should not rely on BPC-157 for alcohol protection: Anyone with diagnosed liver disease (cirrhosis, hepatitis, fatty liver disease) People with alcohol use disorder who need medical treatment, not peptide supplementation Anyone taking hepatotoxic medications (acetaminophen at high doses, certain statins, methotrexate) Individuals with bleeding disorders or on anticoagulants BPC-157 is not a substitute for medical care
This double blind, placebo-controlled, investigator-initiated clinical trial is registered in the Netherlands Trial Register (NTR3858)
Safety risks in the GLP-1 market: an update on weight loss medication, May 2026 Drug shortages and coverage gaps have led to criminal counterfeiters exploiting Americans demand for blockbuster diabetes and weight loss drugs made with semaglutide and tirzepatide
The funding sources of this study had no role in study design, data collection and analysis, decision to publish, or preparation of the article
The maximum penalty is a fine of $2,200 and/or imprisonment for 6 months